02179 瑞科生物－Ｂ
按盘价 
4.620 +0.020 (+0.435%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -32.976% | -27.257% | -25.444% | -34.180% | -44.336% |
| 股东资金回报率 (%) | -98.836% | -70.265% | -41.851% | -43.338% | -197.906% |
| 资本运用回报率 (%) | -49.885% | -51.089% | -32.833% | -36.489% | -36.943% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 88.276% | N/A | N/A | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -3628.556% | N/A | N/A | N/A | N/A |
| 税前边际利润率 (%) | -4779.428% | N/A | N/A | N/A | N/A |
| 纯利率 (%) | -4796.401% | N/A | N/A | N/A | N/A |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 1.000 X | 0.780 X | 2.542 X | 4.316 X | 9.294 X |
| 速动比率 (X) | 0.924 X | 0.706 X | 2.331 X | 4.145 X | 9.125 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 59.937% | 72.719% | 51.015% | 28.426% | 12.814% |
| 总债项 / 总资产比率 (%) | 36.239% | 45.824% | 29.767% | 12.237% | 3.997% |
| 净债项 / 总资产比率 (%) | 16.269% | 29.381% | -8.425% | -45.139% | -57.619% |
| 总债项 / 股东资金比率 (%) | 90.456% | 167.968% | 60.740% | 17.007% | 4.585% |
| 长期债项 / 股东资金比率 (%) | 53.245% | 71.578% | 55.044% | 15.697% | 4.115% |
| 净债项 / 股东资金比率 (%) | 40.608% | 107.695% | -17.191% | -62.732% | -66.088% |
| 净现金 / (债项) ($) | (2.87亿) | (5.70亿) | 1.84亿 | 10.43亿 | 11.06亿 |
| 每股净现金 / (债项) ($) | (0.458) | (1.180) | 0.381 | 2.159 | -- |
| 总债项 / 资本运用比率 (%) | 52.181% | 80.767% | 37.358% | 14.270% | 4.310% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 12633.844日 | -- | -- | -- | -- |
| 应收贸易帐周转率日数 (日) | 19.073日 | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 1100.708日 | N/A | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为25/03/2026 18:00 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -610,390 |
| 增长率 | 8.535% |
| 每股盈利/(亏损) | RMB -1.150 |
| 每股账面资产净值 (¥) | RMB 1.127 |